The Bulletin
The Times


.

NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia

  • Written by PR Newswire

SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer in Australia in the Phase I first-in-human clinical trial of...

The Bulletin Magazine

Practical Guide to Roller Shutters for Safer, More Comfortable Homes

Why the Advertised Rate on a Bonus Saver Account Isn't What Most Savers Actually Earn

The Essential Bathroom Renovation Supplies Checklist Before You Start

Pull Up Stands: A Convenient Display Option for Events and Promotions

How Mining Hose Selection Can Improve Material Transfer Systems

Electric Sliding Door: What to Consider Before Choosing One

What Is Included in a Professional Roof Repair Service on the Gold Coast?

The Unglamorous Baby Buys That Save Australian Parents the Most Time

Cryptocurrency Trading in 2026_ Why Regulated Education Is the New Standard

How Mining Hose Routing Can Influence Wear and Transfer Efficiency

Cryotherapy in Melbourne: What Skin Lesions Can Be Treated with Targeted Cold Therapy?

10 Restaurants in Cranbourne You Need to Try Before 2027

hacklink hack forum hacklink film izle hacklink VipparkPadişahbetGalabetholiganbetholiganbetholiganbetcasinos not on gamstopnon uk casinosnot on gamstopcasinos not on gamstopcasinos non gamblock ukiptviptv satın alzlibraryzlibraryz-libraryjojobet girişdeneme bonusuPadişahbetVipparkPadişahbetdeneme bonusujojobet girişPadişahbetcanlı maç izleMultiwin girişjojobetjojobetjojobetviljo kasinot kirjautuminenGalabetzimpler kasinotGalabet1xbetjojobetjojobet